Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities

  title={Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities},
  author={Branka Radic-Sarikas and Kalliopi Tsafou and Kristina B. Emdal and Theodore Papamarkou and Kilian V. M. Huber and Cornelia N. Mutz and Jeffrey A. Toretsky and Keiryn L. Bennett and Jesper Velgaard Olsen and S{\o}ren Brunak and Heinrich Kovar and Giulio Superti-Furga},
  journal={Molecular Cancer Therapeutics},
  pages={101 - 88}
Improvements in survival for Ewing sarcoma pediatric and adolescent patients have been modest over the past 20 years. Combinations of anticancer agents endure as an option to overcome resistance to single treatments caused by compensatory pathways. Moreover, combinations are thought to lessen any associated adverse side effects through reduced dosing, which is particularly important in childhood tumors. Using a parallel phenotypic combinatorial screening approach of cells derived from three… 

Figures from this paper

Novel Targeted Therapeutic Strategies for Ewing Sarcoma
This review examines the dynamics of ES signaling as it related to both ES and the microenvironment by integrating genomic and proteomic analyses and highlights recent and ongoing studies integrating metabolomics and genomics aimed at better understanding the complex interactions as to how ES adapts to changing biochemical changes within the tumor microenvironment.
The multikinase inhibitor EC‐70124 synergistically increased the antitumor activity of doxorubicin in sarcomas
The capability of the novel multikinase inhibitor EC‐70124 to counteract drug resistance in sarcoma is uncovered and its therapeutic potential when combined with current treatments is highlighted.
The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma
  • W. Jin
  • Biology, Medicine
    Frontiers in Cell and Developmental Biology
  • 2020
This review describes the recent progress related to cellular and molecular functional roles of tyrosine kinases in the progression of ES.
Systems Biology Analysis for Ewing Sarcoma.
It is concluded that despite the seeming simplicity of the oncogene action of EwS, a lot has yet to be understood on the systems-wide mechanisms connecting the driver mutation and the major cellular phenotypes of this pediatric cancer.
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
It is shown that Ewing sarcoma cells are sensitive to treatment with clofarabine, which is a nucleoside analogue and allosteric inhibitor of R NR, and gemcitabine is an irreversible inhibitor of the RRM1 subunit of RNR, which identifies a candidate therapeutic target, and drug combination, in Ewing Sarcoma.
Current Status of Proteomics in Ewing's Sarcoma
  • T. Kondo
  • Biology, Medicine
    Proteomics. Clinical applications
  • 2019
Proteomic approaches have been used to assess the effects of unique genes and drugs on Ewing's sarcoma and to determine specific biomarker candidates for the prediction of drug resistance and recurrence, and revealed the regulation of IL‐6 secretion by EWS‐FLI‐1, which may promote malignant behavior in tumor cells.
Epigenetic and Transcriptional Signaling in Ewing Sarcoma—Disease Etiology and Therapeutic Opportunities
The chemical, RNAi, and CRISPR-cas9 high throughput screens conducted in EwS are summarized with the goal of assisting in the development of novel therapies to treat this aggressive disease.
Precision medicine in Ewing sarcoma: a translational point of view
This review summarizes the preclinical and clinical investigational knowledge about prognostic and targetable biomarkers in Ewing sarcoma, finally suggesting a workflow for precision medicine committees.
The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
This review highlights key studies focusing on IGF signaling in bone sarcomas, specifically studies underscoring novel properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited.
Ewing Sarcoma: Methods and Protocols
This recommended analytical framework for germline and somatic investigations, along with genomic data from growing EwS case series, is expected to aid in accelerating new genomic discoveries in EwWS and expand knowledge of the genetic architecture of EWS.


An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
The multilayered chemical biology approach presented here identified a specific vulnerability of Ewing's sarcoma to concomitant inhibition of Aurora kinases A and B by tozasertib and danusertib, which has the potential to become a new therapeutic option.
Targeted therapies for advanced Ewing sarcoma family of tumors.
The genomic landscape of pediatric Ewing sarcoma.
Next-generation sequencing of Ewing sarcoma found remarkably few mutations, however, it was discovered that loss of STAG2 expression occurs in 15% of tumors and is associated with metastatic disease, suggesting a potential genetic vulnerability in Ewing Sarcoma.
Small‐molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma
The results suggest that midostaurin might be a novel drug that is active against Ewing's cells, which might act by modulating the expression of EWS/FLI1 target genes.
New Strategies in Ewing Sarcoma: Lost in Translation?
Some of the promising therapies that have the potential to change the Ewing sarcoma therapeutic paradigm in the not-too-distant future: insulin-like growth factor receptor inhibitors, targeting of the fusion protein, epigenetic manipulation, PARP inhibitors, and immunotherapy are outlined.
NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma
A number of solid tumors, such as alveolar rhabdomyosarcoma, synovial sarcoma, and myxoid liposarcoma, are associated with recurrent translocation events that encode fusion proteins. Ewing's sarcoma
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Tumors that harbor STAG2 and TP53 mutations have a particularly dismal prognosis with current treatments and require alternative therapies, and novel drugs that target epigenetic regulators may constitute viable therapeutic strategies in a subset of patients with mutations in chromatin modifiers.
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation
The largest genomic survey to date of 101 EFT (65 tumors and 36 cell lines) is reported, finding that EFT has a very low mutational burden but frequent deleterious mutations in the cohesin complex subunit STAG2 and that 11% of tumors pathologically diagnosed as EFT lack a typical EWSR1 fusion oncogene and these tumors do not have a characteristic Ewing sarcoma gene expression signature.
Mapping the Pathways of Resistance to Targeted Therapies.
By combining systematic resistance pathway mapping methods with studies revealing biomarkers of specific resistance pathways and pharmacologic approaches to block these pathways, it may be possible to rationally construct drug combinations that yield more penetrant and lasting responses in patients.